These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 27009796)

  • 21. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
    Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
    J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.
    Stawowczyk E; Kawalec P
    Pharmacoeconomics; 2018 Apr; 36(4):419-434. PubMed ID: 29260508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
    Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
    Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of reporting quality of economic evaluations in plastic surgery based on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Miroshnychenko A; Uhlman K; Malone J; Waltho D; Thoma A
    J Plast Reconstr Aesthet Surg; 2021 Oct; 74(10):2458-2466. PubMed ID: 34217645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic review of economic evaluations of preoperative smoking cessation for preventing surgical complications.
    McCaffrey N; Higgins J; Greenhalgh E; White SL; Graves N; Myles PS; Cunningham JE; Dean E; Doncovio S; Briggs L; Lal A
    Int J Surg; 2022 Aug; 104():106742. PubMed ID: 35764251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J; He T; Lopez-Olivo MA
    Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluations of screening strategies for the early detection of colorectal cancer in the average-risk population: A systematic literature review.
    Mendivil J; Appierto M; Aceituno S; Comas M; Rué M
    PLoS One; 2019; 14(12):e0227251. PubMed ID: 31891647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
    Pelligra CG; Parikh K; Guo S; Chandler C; Mouro J; Abouzaid S; Ailawadhi S
    Clin Ther; 2017 Oct; 39(10):1986-2005.e5. PubMed ID: 28967482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
    Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
    Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
    PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.
    Loveman E; Jones J; Hartwell D; Bird A; Harris P; Welch K; Clegg A
    Health Technol Assess; 2010 Mar; 14(19):1-204. PubMed ID: 20356561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
    Chen Y; Lairson DR; Chan W; Huo J; Du XL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses.
    Wang Y; Camateros P; Smith D; Dawe D; Ellis P
    Syst Rev; 2019 Jun; 8(1):139. PubMed ID: 31186068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review.
    Fu S; Wu CF; Wang M; Lairson DR
    Pharmacoeconomics; 2019 Dec; 37(12):1421-1449. PubMed ID: 31392666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and effectiveness of different methods of earwax removal: a systematic review and economic evaluation.
    Clegg AJ; Loveman E; Gospodarevskaya E; Harris P; Bird A; Bryant J; Scott DA; Davidson P; Little P; Coppin R
    Health Technol Assess; 2010 Jun; 14(28):1-192. PubMed ID: 20546687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review.
    Guets W; Al-Janabi H; Perrier L
    Pharmacoeconomics; 2020 Apr; 38(4):341-356. PubMed ID: 31853801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of lenalidomide in multiple myeloma.
    Schey S; Higginson I
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):229-38. PubMed ID: 20545587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
    Geng J; Yu H; Mao Y; Zhang P; Chen Y
    Pharmacoeconomics; 2015 Jun; 33(6):581-97. PubMed ID: 25736235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.